Ad is loading...
HERVX
Price
$10.11
Change
-$0.03 (-0.30%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

HERVX vs RNWFX

Header iconHERVX vs RNWFX Comparison
Open Charts HERVX vs RNWFXBanner chart's image
Hartford Emerging Markets Equity R6
Price$10.11
Change-$0.03 (-0.30%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
HERVX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
HERVX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HERVX is a Sell and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. HERVX (346M). HERVX pays higher dividends than RNWFX: HERVX (3.83) vs RNWFX (1.51). HERVX was incepted earlier than RNWFX: HERVX (7 years) vs RNWFX (23 years). HERVX is a more actively managed with annual turnover of: 93.00 vs. RNWFX (32.00). HERVX has a lower initial minimum investment than RNWFX: HERVX (0) vs RNWFX (250). HERVX annual gain was more profitable for investors over the last year : 18.69 vs. RNWFX (11.54). HERVX return over 5 years is better than : 26.93 vs. RNWFX (17.17).
HERVXRNWFXHERVX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence7 years23 years-
Gain YTD13.4687.099190%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets346M60.9B1%
Annual Yield % from dividends3.831.51254%
Returns for 1 year18.6911.54162%
Returns for 3 years1.31-14.55-9%
Returns for 5 years26.9317.17157%
Returns for 10 yearsN/A41.00-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics